ERBB2 and breast cancer: In supporting the association of HER2 mutations with trastuzumab resistance, the frequency of acquired HER2 mutations in patients with advanced BC after trastuzumab treatment is much higher compared to patients with early-stage tumors, and an enrichment of HER2 mutations in metastatic lesions from patients undergoing adjuvant trastuzumab has been reported (64, 68).